Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions
Name:
36976821.pdf
Size:
350.6Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Georgi, T. W.Kurch, L.
Hasenclever, D.
Warbey, V. S.
Pike, L.
Radford, John A
Sabri, O.
Kluge, R.
Barrington, S. F.
Affiliation
Department of Nuclear Medicine, University of Leipzig, Leipzig, GermanyIssue Date
2023
Metadata
Show full item recordAbstract
Introduction: Interim PET (iPET) assessment is important for response adaptation in Hodgkin lymphoma (HL). The current standard for iPET assessment is the Deauville score (DS). The aim of our study was to evaluate the causes of interobserver variability in assigning the DS for iPET in HL patients and to make suggestions for improvement. Methods: All evaluable iPET scans from the RAPID study were re-read by two nuclear physicians, blinded to the results and patient outcomes in the RAPID trial. The iPET scans were assessed visually according to the DS and, thereafter, quantified using the qPET method. All discrepancies of more than one DS level were re-evaluated by both readers to find the reason for the discordant result. Results: In 249/441 iPET scans (56%) a concordant visual DS result was achieved. A "minor discrepancy" of one DS level occurred in 144 scans (33%) and a "major discrepancy" of more than one DS level in 48 scans (11%). The main causes for major discrepancies were 1) different interpretation of PET-positive lymph nodes-malignant vs. inflammatory; 2) lesions missed by one reader and 3) different assessment of lesions in activated brown fat tissue. In 51% of the minor discrepancy scans with residual lymphoma uptake, additional quantification resulted in a concordant quantitative DS result. Conclusion: Discordant visual DS assessment occurred in 44% of all iPET scans. The main reason for major discrepancies was the different interpretation of PET positive lymph nodes as malignant or inflammatory. Disagreements in evaluation of the hottest residual lymphoma lesion can be solved by the use of semi-quantitative assessment.Citation
Georgi TW, Kurch L, Hasenclever D, Warbey VS, Pike L, Radford J, et al. Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions. PloS one. 2023;18(3):e0283694. PubMed PMID: 36976821. Pubmed Central PMCID: PMC10047538. Epub 2023/03/29. eng.Journal
PLoS OneDOI
10.1371/journal.pone.0283694PubMed ID
36976821Additional Links
https://dx.doi.org/10.1371/journal.pone.0283694Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0283694
Scopus Count
Collections
Related articles
- Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
- Authors: Biggi A, Bergesio F, Chauvie S, Bianchi A, Menga M, Fallanca F, Hutchings M, Gregianin M, Meignan M, Gallamini A
- Issue date: 2021 Dec
- Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
- Authors: Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, Castellino SM
- Issue date: 2023 Aug 1
- Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
- Authors: Del Puig Cózar-Santiago M, García-Garzón JR, Moragas-Freixa M, Soler-Peter M, Bassa Massanas P, Sánchez-Delgado M, Sanchez-Jurado R, Aguilar-Barrios JE, Sanz-Llorens R, Ferrer-Rebolleda J
- Issue date: 2017 Sep-Oct
- Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
- Authors: Al-Ibraheem A, Anwer F, Juweid ME, Shagera QA, Khalaf AN, Obeidat S, Mansour A, Ma'koseh M, Halahleh K, Jaradat I, Almasri N, Mansour A
- Issue date: 2022 Oct 21
- Interim FDG(18)-PET SUV(max) Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma.
- Authors: Duarte S, Roque A, Saraiva T, Afonso C, Marques BA, Lima CB, Neves D, Lai AC, Costa G, Cipriano A, Geraldes C, Ruzickova L, Carda JP, Gomes M
- Issue date: 2023 Feb